GLMD — Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ
- Employees: 3
- Website: https://galmedpharma.com
Latest SEC filings for GLMD
- 6-K — 2026-09-09
- 6-K — 2026-09-08
- EFFECT — 2026-09-04
- 6-K — 2026-09-03
- 6-K — 2026-09-02
- 6-K — 2026-09-02
- 6-K — 2026-08-19
- 6-K/A — 2026-08-19
- 6-K — 2026-08-17
- 6-K — 2026-08-14
Educational tool only — not investment advice.